Official UK procurement notice
NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024
Authority: NHS England (Central government)
What is being bought4 lots · detail below
Published requirement descriptionProject Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024<br/> <br/>Offer reference number: CM/PHR/22/5678<br/> <br/>CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/><br/>CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.<br/><br/>CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months<br/><br/>CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months
CPV: Pharmaceutical products
How this framework works
From the published notice- Bids received
- 21 bids on the busiest of 4 lots · 38 suppliers appointed
- Framework period
- 1 yr 6 mo from 1 Mar 2024
Lots and requirements (4)Procurement structure
4 lots · all with a published valueLot #1CM/PHR/22/5678/01AwardedPublished value£377,682,000
CM/PHR/22/5678/01 - NHS Framework for North of England Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Lot #2CM/PHR/22/5678/02AwardedPublished value£823,674,000
NHS Framework for North of England Branded Medicines - Lot 2. (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Lot #3CM/PHR/22/5678/03AwardedPublished value£138,947,000
CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
Lot #4CM/PHR/22/5678/04AwardedPublished value£493,031,000
CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
- “NHS Branded Medicines Framework for North of England and Midlands and…” is a framework: the contest is a place on its panel, not a single contract.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 24 Oct 2023, 10:12 BST
- Last source update
- 26 Feb 2024, 12:50 GMT
- Award evaluation window
- 24 Nov 2023 – …
- Authority reference
CM/PHR/22/5678- FTS notice number
2024/S 000-006097- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-040e74Find a Tender
- Electronic trading
- electronic ordering · electronic payment
Publisher note: Please note that Lot 1 was also awarded to Kent Pharma Ltd in addition to those listed under the awarded suppliers below
How it was run
Official noticeTender documents are also served through a separate tool: https://health-family.force.com/s/Welcome ↗
- Appointment period ends
- 23 Nov 2023, 13:00 GMT
- Submission channel
- {"electronicSubmission","written"}
- Accepted languages
- en
- Bids opened
- 24 Nov 2023, 13:00 GMT
Timeline
23 Nov 2023 → 1 Mar 2024 · 5 dates- Admission / appointment period endsperiod end, not a bid countdown23 Nov 2023, 13:00 GMT
- Bids opened24 Nov 2023, 13:00 GMT
- Bids must remain valid until22 Feb 2024, 23:59 GMT
- Notice published26 Feb 2024, 12:50 GMT
- Contract starts1 Mar 2024
Notice history
2 events · 3 releases on Find a Tender · since 24 Oct 2023- Deadline moved to 23 Nov 2023, 13:00 GMT24 Oct 2023, 11:06 BST-1 days · was 24 Nov 2023, 13:00 GMT
- Status changed to complete26 Feb 2024, 12:50 GMT
Published amendments (1 · 1 deadline change)
| When | What | Before | After | Shift |
|---|---|---|---|---|
| — | Contract periodII.2.7.4 | 1 Aug 2025 | 1 Aug 2026 | +365 d |
| — | DeadlineIV.2.2.1 | 24 Nov 2023 | 23 Nov 2023 | -1 d |
| — | Bid openingIV.2.7.1 | 24 Nov 2023 | 23 Oct 2023 | -32 d |
| — | Bid validityIV.2.6.1 | 22 Feb 2024 | 21 Oct 2023 | -124 d |
1 amendment published without a description.
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast74 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
All 20 of these contracts carry the same published figure, £1, the framework's maximum for the whole notice, not each contract's own value. They are not eleven separate sums.
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B)
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B)
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B)
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B)
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B)
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B)
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B)
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B)
- Signed
- 26 Jan 2024
- Value
- ceiling above
- Period
- … – 31 Aug 2025
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 1 · CM/PHR/22/5678/01 | 21bids · 21 electronic · 21 from abroad | 5 | — | — |
| 2 · CM/PHR/22/5678/02 | 21bids · 21 electronic · 21 from abroad | 4 | — | — |
| 3 · CM/PHR/22/5678/03 | 15bids · 15 electronic · 15 from abroad | 5 | — | — |
| 4 · CM/PHR/22/5678/04 | 20bids · 20 electronic · 20 from abroad | 4 | — | — |
Contracting authority & participating public bodies
Framework contractors & participating bidders
38 commercial parties on the notice- Abbvie LtdFramework contractor
- Accord-UK LtdFramework contractor
- AlmirallFramework contractor
- Amgen LtdFramework contractor
- AstraZenecaFramework contractor
- Aventis Pharma ltd t/a SanofiFramework contractor
- Bayer PlcFramework contractor
- BiogenFramework contractor
- CST Pharma LimitedFramework contractor
- Celltrion Healthcare United Kingdom LimitedFramework contractor
Show 28 more suppliers
- Chugai Pharma UK LtdFramework contractor
- Dr.Reddy's Laboratories (UK) LimitedFramework contractor
- Eli Lilly and Company LtdFramework contractor
- Galapagos Biotech LtdFramework contractor
- Gedeon Richter UK LtdFramework contractor
- GlaxoSmithKline UK LimitedFramework contractor
- IpsenFramework contractor
- Janssen-Cilag LtdFramework contractor
- Merck Serono LimitedFramework contractor
- Merck Sharpe and Dohme (UK) LimitedFramework contractor
- MerzFramework contractor
- MylanFramework contractor
- Napp Pharmaceuticals LtdFramework contractor
- Neon Healthcare LtdFramework contractor
- Novartis Pharmaceuticals UK LtdFramework contractor
- Novo NordiskFramework contractor
- Organon Pharmaceuticals UK LtdFramework contractor
- Orifarm UKFramework contractor
- Pfizer LtdFramework contractor
- Pharmacosmos UK LtdFramework contractor
- Roche Products LtdFramework contractor
- Sandoz LtdFramework contractor
- Sobi (Swedish Orphan Biovitrum Ltd)Framework contractor
- Sun Pharma UK LtdFramework contractor
- Teva UK LimitedFramework contractor
- Thornton and Ross LtdFramework contractor
- Vifor Pharma UK LtdFramework contractor
- Zentiva Pharma UK LtdFramework contractor
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.